​

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MDGL Stock Forecast

Madrigal Pharmaceuticals (MDGL) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $315.75, with a high of $410.00 and a low of $111.00. This represents a -7.35% decline from the last price of $340.80.

$100 $170 $240 $310 $380 $450 High: $410 Avg: $315.75 Low: $111 Last Closed Price: $340.8

MDGL Stock Rating

Madrigal Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (88.89%), 2 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 2 16 Strong Sell Sell Hold Buy Strong Buy

MDGL Price Target Upside V Benchmarks

TypeNameUpside
StockMadrigal Pharmaceuticals-7.35%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$363.00
Last Closing Price$340.80$340.80$340.80
Upside/Downside--6.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254101-116
Mar, 25492-116
Feb, 25392-115
Jan, 25492-116
Dec, 24493-117
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 29, 2024Yasmeen RahimiPiper Sandler$336.00$221.7651.52%-1.41%
May 09, 2024Ed AcreH.C. Wainwright$390.00$208.0487.46%14.44%
Mar 19, 2024Liisa BaykoEvercore ISI$405.00$265.6852.44%18.84%
Mar 15, 2024Eliana MerleUBS$410.00$270.3751.64%20.31%
Mar 15, 2024Akash TewariJefferies$400.00$270.3747.95%17.37%
Mar 15, 2024Ed AcreH.C. Wainwright$425.00$270.3757.19%24.71%
Mar 15, 2024Jonathan WollebenJMP Securities$397.00$270.3746.84%16.49%
Mar 15, 2024Mayank MamtaniB.Riley Financial$270.00$270.37-0.14%-20.77%
Jan 05, 2023JMP Securities$390.00$274.4842.09%14.44%
Dec 21, 2022UBS$337.00$257.1231.07%-1.12%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 14, 2025H.C. WainwrightBuyBuyhold
Jul 16, 2024JMP SecuritiesOutperformOutperformhold
Jun 28, 2024Cantor FitzgeraldNeutralinitialise
Jun 10, 2024Wolfe ResearchOutperforminitialise
Jun 06, 2024CitigroupBuyBuyhold
May 29, 2024Piper SandlerOverweightOverweighthold
May 10, 2024B. RileyNeutralNeutralhold
May 09, 2024H.C. WainwrightBuyBuyhold
Apr 22, 2024Bank of America SecuritiesUnderperforminitialise
Dec 21, 2022UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-50 $-20 $10 $40 $70 $100 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-12.78$-19.99$-21.90----
Avg Forecast$-12.93$-19.44$-23.62$-12.97$2.87$32.05$57.26
High Forecast$-6.02$-18.30$-22.60$-3.19$9.94$46.90$75.38
Low Forecast$-19.37$-20.11$-24.76$-22.28$-4.22$7.13$34.14
Surprise %-1.16%2.83%-7.28%----

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--$180.13M----
Avg Forecast$9.18M-$172.04M$514.95M$1.02B$1.88B$2.92B
High Forecast$11.02M-$182.74M$633.56M$1.02B$1.94B$3.64B
Low Forecast$7.34M-$161.27M$412.06M$1.02B$1.82B$2.02B
Surprise %--4.71%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-197.44M$-373.63M$-465.89M----
Avg Forecast$-172.74M$-373.63M$-442.50M$-297.44M$117.58M$782.67M$1.07B
High Forecast$-138.19M$-342.06M$-422.26M$-59.61M$185.69M$876.45M$1.41B
Low Forecast$-207.29M$-375.85M$-462.74M$-416.30M$-78.80M$133.33M$637.91M
Surprise %14.30%-5.29%----

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals stock a buy?

Madrigal Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Madrigal Pharmaceuticals is a favorable investment for most analysts.

What is Madrigal Pharmaceuticals's price target?

Madrigal Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $315.75 over the next 12 months. The price target range spans from $111 at the low end to $410 at the high end, suggesting a potential -7.35% change from the previous closing price of $340.8.

How does Madrigal Pharmaceuticals stock forecast compare to its benchmarks?

Madrigal Pharmaceuticals's stock forecast shows a -7.35% downside, underperforming the average forecast for the healthcare stocks sector (30.37%) and underperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Madrigal Pharmaceuticals over the past three months?

  • April 2025: 25.00% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 6.25% Strong Sell.
  • March 2025: 25.00% Strong Buy, 56.25% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.
  • February 2025: 20.00% Strong Buy, 60.00% Buy, 13.33% Hold, 0% Sell, 6.67% Strong Sell.

What is Madrigal Pharmaceuticals’s EPS forecast?

Madrigal Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-12.97, marking a -40.78% decrease from the reported $-21.9 in 2024. Estimates for the following years are $2.87 in 2026, $32.05 in 2027, and $57.26 in 2028.

What is Madrigal Pharmaceuticals’s revenue forecast?

Madrigal Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $514.95M, reflecting a 185.87% increase from the reported $180.13M in 2024. The forecast for 2026 is $1.02B, followed by $1.88B for 2027, and $2.92B for 2028.

What is Madrigal Pharmaceuticals’s net income forecast?

Madrigal Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-297M, representing a -36.16% decrease from the reported $-466M in 2024. Projections indicate $117.58M in 2026, $782.67M in 2027, and $1.07B in 2028.